Search results
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Zacks via Yahoo Finance· 10 months agoSeagen Inc. SGEN announced positive top-line results from its late-stage HER2CLIMB-02 study,...
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance· 2 years agoImmunoGen, Inc. IMGN incurred a loss of 24 cents per share for second-quarter 2022, wider than the...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Zacks via Yahoo Finance· 2 years agoShares of Puma Biotechnology PBYI were up 17.4% at market close on Aug 5, following the earnings...
An Important History Lesson for Gene-Editing Investors
Motley Fool· 6 months agoThe history of biotechnology is full of examples of promising technologies that took decades to...
Seagen Inc. (SGEN) Q3 2022 Earnings Call Transcript
Motley Fool· 2 years agoSpeakers on today's call will be Roger Dansey, interim chief executive officer and chief medical officer; Todd Simpson, chief financial officer; and Chip...
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 3 weeks agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Zacks via Yahoo Finance· 2 months agoRoche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue...
Why Gilead Sciences Stock Was a 5% Winner Today
Motley Fool· 2 years agoGilead Sciences (NASDAQ: GILD) stock was off to a good start this week, rising by more than 5% on Monday against the modest (0.4%) gain of the S&P 500 index. The prominent pharmaceutical company ...
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
Zacks via Yahoo Finance· 4 months agoRoche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in...